Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer.

ABSTRACT:

Lessons learned

Neoadjuvant bevacizumab with modified FOLFOX7 without radiation failed to meet the goal of pathological complete response rate; however, the low number of recurrence and disease-free survival in this population, with predominantly stage III, is encouraging and worth further exploration. The racial distribution of the patient population, as well as a wait time of more than 4 weeks after last chemotherapy, may have contributed to the findings.

Background

Combination chemotherapy in lieu of radiation in rectal adenocarcinoma is under exploration in multiple trials. We evaluated the efficacy of neoadjuvant FOLFOX + bevacizumab in patients (pts) with clinical stage II and III disease.

Methods

Pts received six cycles of bevacizumab (5 mg/kg) and modified FOL

SUBMITTER: Barzi A 

PROVIDER: S-EPMC8186403 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature